Alberto Bardelli

Active 1991–2025

204
Papers
67,714
Citations
115
h-index
196
i10-index

Citations

Citations per year for Alberto Bardelli1981: 1 citations1987: 1 citations1991: 5 citations1992: 17 citations1993: 22 citations1994: 40 citations1995: 40 citations1996: 90 citations1997: 77 citations1998: 95 citations1999: 114 citations2000: 146 citations2001: 113 citations2002: 127 citations2003: 137 citations2004: 196 citations2005: 260 citations2006: 258 citations2007: 264 citations2008: 288 citations2009: 365 citations2010: 486 citations2011: 478 citations2012: 456 citations2013: 503 citations2014: 680 citations2015: 793 citations2016: 846 citations2017: 1,063 citations2018: 982 citations2019: 3,063 citations2020: 3,089 citations2021: 3,085 citations2022: 2,355 citations2023: 1,697 citations2024: 2,637 citations2025: 1,313 citations2026: 45 citations1982–1986: no citations, so these years are not shown1988–1990: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 6,995 citing papers, 25.4% of this breakdownChina: 3,378 citing papers, 12.3% of this breakdownItaly: 2,046 citing papers, 7.4% of this breakdownUnited Kingdom: 1,595 citing papers, 5.8% of this breakdownGermany: 1,405 citing papers, 5.1% of this breakdownFrance: 1,138 citing papers, 4.1% of this breakdownJapan: 1,020 citing papers, 3.7% of this breakdownSpain: 956 citing papers, 3.5% of this breakdownNetherlands: 776 citing papers, 2.8% of this breakdownCanada: 728 citing papers, 2.7% of this breakdownAustralia: 678 citing papers, 2.5% of this breakdownSwitzerland: 573 citing papers, 2.1% of this breakdown
0%25.4%Other 22.6%

Fields

  • Medicine46.6%
  • Biochemistry, Genetics and Molecular Biology46.1%
  • Immunology and Microbiology2.2%
  • Engineering1.2%
  • Computer Science0.8%
  • Neuroscience0.6%
  • Other2.5%

Topics

  • Cancer Genomics and Diagnostics8.9%
  • Colorectal Cancer Treatments and Studies4.8%
  • Lung Cancer Treatments and Mutations3.6%
  • Genetic factors in colorectal cancer3.5%
  • Cancer Cells and Metastasis2.9%
  • PI3K/AKT/mTOR signaling in cancer2.7%
  • Other73.6%

Coauthors

All papers

Open in search
  1. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Calogero Lauricella, Michael Lim, Evan J. Lipson, Suely Kazue Nagahashi Marie, George J. Netto, Kelly S. Oliner, Alessandro Olivi, Louise Olsson, Gregory J. Riggins, Andrea Sartore‐Bianchi, Kerstin Schmidt, le-Ming Shih, Sueli Mieko Oba‐Shinjo, Salvatore Siena, Dan Theodorescu, Jeanne Tie, Timothy T. Harkins, Silvio Veronese, Tian‐Li Wang, Jon Weingart, Christopher L. Wolfgang, Laura D. Wood, Dongmei Xing, Ralph H. Hruban, Jian Wu, Peter J. Allen, C. Max Schmidt, Michael A. Choti, Victor E. Velculescu, Kenneth W. Kinzler, Bert Vogelstein, Nickolas Papadopoulos, Luis A. Díaz - Science Translational Medicine 2014 cited by 5,110

  2. Integrating liquid biopsies into the management of cancer

    Authors: , , , - Nature Reviews Clinical Oncology 2017 cited by 1,918

  3. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Demetris Papamichael, George Pentheroudakis, Per Pfeiffer, Timothy Price, Cornelis J.A. Punt, Jens Ricke, A. Roth, Ramón Salazar, Werner Scheithauer, Hans‐Joachim Schmoll, Josep Tabernero, Julien Taı̈eb, Sabine Tejpar, Harpreet Wasan, Takayuki Yoshino, Aziz Zaanan, Dirk Arnold - Annals of Oncology 2016 cited by 3,449

  4. Liquid biopsy: monitoring cancer-genetics in the blood

    Authors: , , , - Nature Reviews Clinical Oncology 2013 cited by 1,852

  5. EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2020 cited by 488

  6. Liquid Biopsies: Genotyping Circulating Tumor DNA

    Authors: , - Journal of Clinical Oncology 2014 cited by 2,207

  7. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

    Authors: , , , , , , , , - Nature 2012 cited by 2,075

  8. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2016 cited by 999

  9. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 cited by 1,009

  10. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2012 cited by 1,914

  11. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2022 cited by 261

  12. High Frequency of Mutations of the PIK3CA Gene in Human Cancers

    Authors: , , , , , , , , , , , , , , - Science 2004 cited by 3,452

  13. Early‐onset colorectal cancer in young individuals

    Authors: , , , , , - Molecular Oncology 2018 cited by 667

  14. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jason E. Faris, Jennifer Y. Wo, François Aguet, Ipsita Dey‐Guha, Mehlika Hazar-Rethinam, Dora Dias‐Santagata, David T. Ting, Andrew X. Zhu, Theodore S. Hong, Todd R. Golub, A. John Iafrate, Viktor A. Adalsteinsson, Alberto Bardelli, Laxmi Parida, Dejan Juric, Gad Getz, Ryan B. Corcoran - Nature Medicine 2019 cited by 522

  15. Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nabeel Bardeesy, Andrew X. Zhu - Cancer Discovery 2016 cited by 545

  16. Adaptive mutability of colorectal cancers in response to targeted therapies

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Science 2019 cited by 446

  17. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Camilla Qvortrup, Tine Plato Hansen, Eric Van Cutsem, Hubert Piessevaux, Diether Lambrechts, Mauro Delorenzi, Sabine Tejpar - The Lancet Oncology 2010 cited by 2,143

  18. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2017 cited by 644

  19. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2014 cited by 912

  20. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Andrea Sartore‐Bianchi, Alberto Bardelli - Nature Medicine 2015 cited by 1,096

  21. Toward understanding and exploiting tumor heterogeneity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2015 cited by 769

  22. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robin Kate Kelley, Alberto Bardelli, A. John Iafrate, William C. Hahn, Cyril H. Benes, David T. Ting, Hiroshi Hirai, Gad Getz, Dejan Juric, Andrew X. Zhu, Ryan B. Corcoran, Nabeel Bardeesy - Cancer Discovery 2019 cited by 371

  23. High-dose vitamin C enhances cancer immunotherapy

    Authors: , , , , , , , , , , , , , , - Science Translational Medicine 2020 cited by 273

  24. A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2011 cited by 953